Lipid Mediators in Lung Anaphylaxis: Kinetics of Their Release and Modulation by Selected Drugs

  • P. Sirois
  • M. Harczy
  • J. Maclouf
  • P. Pradelles
  • P. Braquet
  • P. Borgeat
Part of the NATO ASI Series book series (NSSA, volume 139)


Various arachidonic acid metabolites are released from the lungs during hypersensitivity reactions such as anaphylaxis or asthma. Thromboxane A2 and leukotrienes were shown to play a key role in the bronchoconstriction associated with these conditions. In our experiments, Reverse Phase High Performance Liquid Chromatography (RP-HPLC) and Enzyme Immunoassay (EIA) techniques were use (a) to study the profile of cyclooxygenase and lipoxygenase products released during guinea pig anaphylaxis, (b) to characterize their time-course of release, and (c) to investigate the complex interactions regulating their synthesis. The lungs of guinea pigs sensitized to ovalbumin (100 mg intraperitonealy and 100 mg subcutaneously) were perfused with Krebs solution. Anaphylaxis was induced by specific challenge (ovalbumin, 100 ug/ml) and the effluent was collected at 1 min intervals for the measure of prostaglandin E2 (PGE2), thromboxane B2 (TxB2), leukotrienes B4 (LTB4) and D4 (LTD4). In a set of experiments, the 12-hydroxyheptadecatrienoic acid (HHT) and 12-keto heptadecatrienoic acid (12-keto-HT) were analysed. Our results showed that the time-course of release of all the arachidonic acid metabolites were maximal approximately 5–6 min following the onset of the challenge. Leukotriene D4 and to a higher extent LTB4 were the major lipoxygenase products detected during anaphylaxis. Perfusion of the lungs with aspirin and indomethacin decreased the formation of PGE2 and TxB2 but did not modify the release of leukotrienes. On the contrary, BW755C and eicosatetraynoic acid (ETYA) reduced the release of all icosanoids from the lungs. FPL-55712, a selective leukotriene antagonist, significantly reduced the release of PGE2, TxB2, LTB4 and LTD4 at the high concentration (20 uM). In summary, this study made use of novel techniques to quantify arachidonic acid metabolites in the effluent of perfused lungs. New metabolites were described. Our study also stresses the possible significance of LTB4 as a mediator of anaphylaxis and asthma.


Reverse Phase High Performance Liquid Chromatography Center Panel Arachidonic Acid Metabolite Lipoxygenase Product Cyclooxygenase Product 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hammarstrom S, Murphy RC, Samuelsson B, Clark DA, Mioskowski C, Corey EJ. Biochem. Biophvs. Res. Commun, 91: 1266 (1979).CrossRefGoogle Scholar
  2. 2.
    Murphy RC, Hammarstrom S, Samuelsson B. Proc. Natl. Acad. Sci. U.S.A. 76: 4279 (1979).CrossRefGoogle Scholar
  3. 3.
    Morris HR, Taylor GW, Piper PJ, Samhoun MN, Tippins JR. Prostaglandins. 19: 185 (1980).PubMedCrossRefGoogle Scholar
  4. 4.
    Kellaway CH, Trethewie ER. Q. J. Exp. Physiol. 30: 185 (1980).Google Scholar
  5. 5.
    Brocklehurst WE. In: P Kallos, BH Waksman. Progress in Allergy. Basel, Karger, p: 539 (1962). Google Scholar
  6. 6.
    Piper PJ, Vane JR. Nature. Lond. 223: 29 (1969).PubMedCrossRefGoogle Scholar
  7. 7.
    Drazen JM, Austen KF, Lewis RA, Clark DA, Goto G, Marfat A, Corey EJ. Proc. Natl. Acad. Sci. U.S.A. 77: 4354 (1980).PubMedCrossRefGoogle Scholar
  8. 8.
    Woodrow Weiss J, Drazen JM, Coles N, McFadden RR, Weller PF, Corey EJ, Lewis RA, Austen KF. Science, 216: 196 (1982).CrossRefGoogle Scholar
  9. 9.
    Borgeat P, Fruteau de Laclos B, Rabinovitch H, Picard S, Braquet P, Hebert J, Laviolette M. J. All. Clin. Immunol. 74: 310 (1984).CrossRefGoogle Scholar
  10. 10.
    Pradelles P, Grassi J, Maclouf, J. Anal. Chem. 57: 1170 (1985).PubMedCrossRefGoogle Scholar
  11. 11.
    Engineer DM, Niederhauser U, Piper PJ, Sirois P. Br. J. Pharmacol., 62: 61 (1978).PubMedGoogle Scholar
  12. 12.
    Salari H, Borgeat P, Braquet P and Sirois P. J. All. Clin. Immunol., 77: 720 (1986).CrossRefGoogle Scholar
  13. 13.
    Sirois P, Brousseau Y, Chagnon M, Gentile J, Gladu M, Salari H and Borgeat P. Exp. Lung Res. 9: 17 (1985).PubMedCrossRefGoogle Scholar
  14. 14.
    Harczy M, Maclouf P, Pradelles P, Braquet P, Borgeat P and Sirois P. Pharmacol. Res. Commun. (in press).Google Scholar
  15. 15.
    Sirois P, Roy S, Borgeat P, Picard S, Corey EJ. Biochem. Biophys. Res. Commun. 99: 385 (1981).PubMedCrossRefGoogle Scholar
  16. 16.
    Sirois P, Roy S, Tetrault JP, Borgeat P, Picard S, Corey EJ. Prostaglandins and Med. 7: 327 (1981).CrossRefGoogle Scholar
  17. 17.
    Sirois P, Harczy M, Braquet P, Borgeat P, Maclouf J and Pradelles P. Advances in Prostaglandin, Thromboxane and Leukotriene Research (submitted).Google Scholar
  18. 18.
    Malik AB, Noonan TC, Selig WM and Garcia JGN. IN: Leukotrienes in Cardiovascular and Pulmonary function. AM Lefer and MH Gee. Alan R Liss, Inc., New York, p: 221 (1985).Google Scholar
  19. 19.
    Liu Y, Yoden K, Shen RF, Tai HH. Biochem. Biophys. Res. Commun. 129: 268 (1985).PubMedCrossRefGoogle Scholar
  20. 20.
    Salari H, Braquet P and Borgeat P. Prostagl. Leukotr. and Med., 13: 53 (1984).CrossRefGoogle Scholar
  21. 21.
    Krell RD, Osborn R, Falcone K, Vickery L. Prostaglandins, 22: 423 (1981).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • P. Sirois
    • 1
  • M. Harczy
    • 1
  • J. Maclouf
    • 2
  • P. Pradelles
    • 3
  • P. Braquet
    • 4
  • P. Borgeat
    • 5
  1. 1.Depts. Pediatrics and Pharmacology, Faculty of MedicineUniversity of SherbrookeSherbrookeP.Q. Canada
  2. 2.Hôpital LariboisièreParisFrance
  3. 3.CEN-SaclayFrance
  4. 4.IHBLe Plessis RobinsonFrance
  5. 5.CHULCanada

Personalised recommendations